- Home
- EKSO vs VIVS Comparison
EKSO vs VIVS Comparison
Compare EKSO & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EKSO | VIVS |
|---|---|---|
| Founded | 2005 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7M | 8.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | EKSO | VIVS |
|---|---|---|
| Price | $5.51 | $1.85 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $7.75 | N/A |
| AVG Volume (30 Days) | ★ 326.9K | 35.5K |
| Earning Date | 10-28-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,749,000.00 | $140,000.00 |
| Revenue This Year | N/A | $42.38 |
| Revenue Next Year | $54.65 | $15.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 35.92 |
| 52 Week Low | $2.73 | $1.41 |
| 52 Week High | $14.97 | $21.96 |
Technical Indicators
Market Signals| Indicator | EKSO | VIVS |
|---|---|---|
| Relative Strength Index (RSI) | 65.38 | 38.95 |
| Support Level | $4.56 | $1.84 |
| Resistance Level | $5.09 | $2.10 |
| Average True Range (ATR) | 0.31 | 0.16 |
| MACD | 0.11 | -0.01 |
| Stochastic Oscillator | 92.68 | 11.40 |
Price Performance
Historical ComparisonAbout EKSO Ekso Bionics Holdings Inc.
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.
About VIVS VivoSim Labs Inc.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.